Will India Figure In First-Wave Markets For Sun's Ilumya?
Executive Summary
Sun’s Ilumya is available in the US and Europe, with China now on the launch radar as well. Scrip examines whether the firm’s home turf India should also be among the early markets for the novel psoriasis asset, amid pressure to maintain the 'price line'.
You may also be interested in...
5 Talking Points As Sun's Cequa Hits Home Turf And There's Restasis
Cequa arrives in India, almost four years post US debut with Sun deploying what has generally been perceived as the text-book launch approach of foreign firms in the country. Scrip delves into the market dynamics in a segment where AbbVie's blockbuster Restasis is well entrenched.
Sun And Hikma Strike Ilumya Deal
Sun has inked another commercial partnership to bring psoriasis drug Ilumya to countries outside India, this time teaming with Hikma in the MENA region.
Sun, Hikma Firm Up Licensing Deal For Ilumya In MENA Region
Deal Snapshot: Sun inks another commercial partnership to bring psoriasis drug Ilumya to countries outside India, this time teaming with Hikma in the MENA region.